Abstract
Accurately evaluating the disease risks after low-dose ionizing radiation (IR) exposure are crucial for protecting public health, setting safety standards, and advancing research in radiation safety. However, while much is known about the disease risks of high-dose irradiation, risk estimates at low dose remains controversial. To date, five different parametric models (supra-linear, linear no threshold, threshold, quadratic, and hormesis) for low doses have been studied in the literature. Different dose-response models may lead to inconsistent or even conflicting results.
In this manuscript, we introduce a data-driven deep neural network (DNN) model designed to evaluate dose-response models at low doses using Life Span Study (LSS) data. DNNs possess the capability to approximate any continuous function with an adequate number of nodes in the hidden layers. Being data-driven, they circumvent the challenges associated with misspecification inherent in parametric models. Our simulation study highlights the effectiveness of DNNs as a valuable tool for precisely identifying dose-response models from available data. New findings from the LSS study provide robust support for a linear quadratic (LQ) dose-response model at low doses.
While the linear no threshold (LNT) model tends to overestimate disease risk at very low doses and underestimate health risk at relatively high doses, it remains a reasonable approximation for the LQ model, given the minor impact of the quadratic term at low doses. Our demonstration underscores the power of DNNs in facilitating comprehensive investigations into dose-response associations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Radiation Effects Research Foundation (RERF), Hiroshima and Nagasaki, Japan is a private, nonprofit foundation funded by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the U.S. Department of Energy (DOE). The research was also funded in part through the DOE award DE-HS0000031 to the National Academy of Sciences. The views of the authors do not necessarily reflect those of the two governments.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The person-year table dataset was downloaded from https://www.rerf.or.jp/en/library/data-en/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email: is144{at}cumc.columbia.edu.
The formulas were not tranferred from words to pdf correctly in the original version.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
